Tolingin, Mary Joy .
HRN: 15-85-16 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/25/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
11/25/2023
11/27/2023
IV
500mg
Q8hrs X 4 Doses
Thickly MSAF
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes